77 related articles for article (PubMed ID: 22138229)
1. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Randall LM; Sill MW; Burger RA; Monk BJ; Buening B; Sorosky JI
Gynecol Oncol; 2012 Mar; 124(3):563-8. PubMed ID: 22138229
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study.
Akers SN; Riebandt G; Miller A; Groman A; Odunsi K; Lele S
Eur J Gynaecol Oncol; 2013; 34(2):113-9. PubMed ID: 23781579
[TBL] [Abstract][Full Text] [Related]
3. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK;
J Clin Oncol; 2024 Apr; 42(11):1301-1310. PubMed ID: 38215359
[TBL] [Abstract][Full Text] [Related]
4. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
6. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Madsen CV; Steffensen KD; Olsen DA; Waldstrøm M; Smerdel M; Adimi P; Brandslund I; Jakobsen A
J Ovarian Res; 2012 Sep; 5(1):23. PubMed ID: 22989094
[TBL] [Abstract][Full Text] [Related]
7. RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
Charnalia M; Chopra S; Mulani J; Popat P; Rath S; Thomeer M; Mittal P; Gupta A; Boere I; Gupta S; Nout RA
Int J Gynecol Cancer; 2024 Jun; 34(6):817-823. PubMed ID: 38649234
[TBL] [Abstract][Full Text] [Related]
8. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
Karamouza E; Glasspool RM; Kelly C; Lewsley LA; Carty K; Kristensen GB; Ethier JL; Kagimura T; Yanaihara N; Cecere SC; You B; Boere IA; Pujade-Lauraine E; Ray-Coquard I; Proust-Lima C; Paoletti X
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980708
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
[No Abstract] [Full Text] [Related]
10. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Monk BJ; Huang HQ; Burger RA; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Liang SX; Wenzel L
Gynecol Oncol; 2013 Mar; 128(3):573-8. PubMed ID: 23219660
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
[TBL] [Abstract][Full Text] [Related]
12. Long-term response to Olaparib in carcinomatous meningitis of a
Favier L; Truc G; Boidot R; Bengrine-Lefevre L
Mol Clin Oncol; 2020 Jul; 13(1):73-75. PubMed ID: 32454976
[TBL] [Abstract][Full Text] [Related]
13. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
14. Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
Tomao F; Vici P; Tomao S
Lancet Oncol; 2020 May; 21(5):616-617. PubMed ID: 32359486
[No Abstract] [Full Text] [Related]
15. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
Ma Y; Chen P; Drisko JA; Khabele D; Godwin AK; Chen Q
Oncol Lett; 2020 Apr; 19(4):2629-2638. PubMed ID: 32218813
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
Patel PR; Senyuk V; Sweiss K; Calip GS; Pan D; Rodriguez N; Oh A; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1273-1279. PubMed ID: 32194286
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
18. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
Arend R; Westin SN; Coleman RL
Int J Gynecol Cancer; 2020 May; 30(5):684-694. PubMed ID: 32079709
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
20. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D; Bologna A; Cecere SC; De Matteis E; Scandurra G; Zamagni C; Arcangeli V; Artioli F; Bella M; Blanco G; Cardalesi C; Casartelli C; De Vivo R; Di Napoli M; Gisone EB; Lauria R; Lissoni AA; Loizzi V; Maccaroni E; Mangili G; Marchetti C; Martella F; Naglieri E; Parolin V; Ricciardi G; Ronzino G; Salutari V; Scarfone G; Secondino S; Spagnoletti I; Tasca G; Tognon G; Guarneri V
Support Care Cancer; 2020 May; 28(5):2435-2442. PubMed ID: 32048043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
